Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasmaTAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD)

José Verdú; Pascual Marco; Susana Benlloch; José Sanchez; Javier Lucas

doi:10.1160/TH05-09-0620

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2006; 95(03): 585-586
DOI: 10.1160/TH05-09-0620

Letters to the Editor

Schattauer GmbH

Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasmaTAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD)

José Verdú

¹Sección de Hemostasia y Trombosis, Hospital General Universitario de Alicante, Alicante, Spain

,

Pascual Marco

¹Sección de Hemostasia y Trombosis, Hospital General Universitario de Alicante, Alicante, Spain

,

Susana Benlloch

²Unidad de Investigatión, Hospital General Universitario de Alicante, Alicante, Spain

,

José Sanchez

²Unidad de Investigatión, Hospital General Universitario de Alicante, Alicante, Spain

,

Javier Lucas

¹Sección de Hemostasia y Trombosis, Hospital General Universitario de Alicante, Alicante, Spain

› Author Affiliations

Abstract

Full Text

References

References
1 Frere C, Morange PE, Saut N. et al. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb Haemost 2005; 94: 373-9.
2 Henry M, Aubert H, Morange PE. et al. Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97: 2053-8.
3 Brouwers GJ, Vos HL, Leebeek FW. et al. A novel possibly functional, single nucleotide polymorphism in the codingregionofthethrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001; 98: 1992-3.
4 Guimaraes AH, van Tilburg NH, Vos HL. et al. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 2004; 124: 659-65.
5 van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
6 Juhan-Vague I, Morange PE, Aubert H. et al. HIF-MECH Study Group. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002; 22: 867-73.
7 Tregouet DA, Aubert H, Henry M. et al. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. Hum Genet 2001; 109: 191-7.
8 Leebeek FW, Goor MP, Guimaraes AH. et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 2005; 03: 2211-8.
9 Eichinger S, Schonauer V, Weltermann A. et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004; 103: 3773-6.
10 Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
11 Gils A, Alessi MC, Brouwers E. et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 1122-7.